Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CELU vs OVID: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OVID Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)

OVID Overall Winner 6-Pillar Tally: CELU 2 – 3 OVID (1 Tie) Matrix Metrics: CELU 2 – 8 OVID

As of Nov 20, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). CELU carries a Unified Composite Score of 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin), whereas OVID carries 52.3/100 (HOLD) at $2.20 (1.8x Forward P/E, -4693.7% operating margin).

  • Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (52.3/100 HOLD vs. CELU 42.9/100 HOLD) and 1.04β · 97% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile OVID is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CELU vs OVID
CELU NASDAQ
Celularity Inc. Class A Common Stock
Pharmaceutical Preparations
$0.46
-1.05% 1D
Market Cap $15.2M
TTM Revenue $19M
Forward P/E N/M
Beta / 30D Vol 2.01β · 135% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 67.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -17.3%), weak momentum, RSI 27
RSI-14: 26.9 · SMA20: $0.71 · SMA50: $1.08
OVID NASDAQ Head-to-Head Winner
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.20
-5.98% 1D
Market Cap $424.6M
TTM Revenue $1.5M
Forward P/E 1.8x
Beta / 30D Vol 1.04β · 97% Vol
Unified Composite Score
52.3 / 100 HOLD
Tech 30.0 Fund 48.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 41
RSI-14: 40.7 · SMA20: $2.49 · SMA50: $2.46

6-Pillar Scorecard Institutional Category Breakdown (CELU 2 – 3 OVID)

Columns: Metric · CELU · OVID
1. Valuation Multiples OVID
Forward P/E N/M 1.8x
Trailing P/E N/M 1.8x
PEG Ratio N/M N/M
EV / Revenue 2.7x N/M
2. Growth & Scale CELU
Revenue Growth (YoY) -5.3% -88.3%
Earnings Growth (YoY) -61.3% +0.0%
TTM Revenue (USD) $19M $1.5M
Market Cap $15.2M $424.6M
3. Profitability & Quality OVID
Gross Margin 19.2% 100.0%
Operating Margin -254.0% -4693.7%
Net Profit Margin -245.7% 0.0%
Return on Equity (ROE) -6367.2% -35.4%
4. Balance Sheet & Cash Flow CELU
Cash Generation (TTM) -$8.9M -$58M
Cash Flow Margin -47.8% N/A
Net Cash / Leverage $35M Net Debt $1.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OVID
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 116.6% (50th %ile) 11.7% (<1st %ile)
Put/Call OI Skew 3.60x (Put-Skewed) 0.18x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CELU (2) vs OVID (8)
Institutional Metric CELU OVID Criterion Row Edge
Market Capitalization
Scale
$15.2M $424.6M Larger Scale OVID
Trailing P/E Ratio
Valuation
N/M 1.8x Lower Multiple OVID
Forward P/E Ratio
Valuation
N/M 1.8x Lower Multiple OVID
Revenue Growth (YoY)
Growth
-5.3% -88.3% Higher Growth CELU
Operating Margin (TTM)
Profitability
-254.0% -4693.7% Higher Margin CELU
Net Profit Margin
Profitability
-245.7% 0.0% Higher Margin OVID
Return on Equity (ROE)
Capital Efficiency
-6367.2% -35.4% Higher ROE OVID
52-Week Range Position
Momentum
2% ($0–$3) 52% ($1–$3) Stronger Trend OVID
Beta / 30D Volatility
Risk Regime
2.01β · 135% Vol 1.04β · 97% Vol Lower Realized Risk OVID
Unified Institutional Score
Composite Signal
42.9 / 100 (HOLD) 52.3 / 100 (HOLD) Higher Composite OVID
Trailing 12M Revenue (USD)
Operating Scale
$19M $1.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
19.2% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.9M ($35M Net Debt) -$58M ($1.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OVID +48.73 pp
CELU: -55.9% · OVID: -7.17%
3M Horizon OVID +18.25 pp
CELU: -40.24% · OVID: -21.99%
6M Horizon OVID +35.86 pp
CELU: -46.79% · OVID: -10.93%
1Y Horizon OVID +144.48 pp
CELU: -72.6% · OVID: +71.88%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CELU Revenue OVID Revenue CELU Op. Margin OVID Op. Margin Margin Leader
FY2020 $10M $10M -1064.0% -645.4% OVID
FY2021 $20M $210M -511.2% 59.6% OVID
FY2022 $20M $0M -142.4% -3696.4% CELU
FY2023 $20M $0M -844.4% -15122.7% CELU
FY2024 $50M $0M -70.7% -10933.7% CELU
FY2025 $30M $10M -230.9% -585.2% CELU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CELU BREAKDOWN
60d in phase · OBV NEUTRAL
Current IV 116.6%
IV Percentile 50th %ile
Put/Call OI Skew 3.60x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OVID BREAKDOWN
154d in phase · OBV DISTRIBUTION
Current IV 11.7%
IV Percentile <1st %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OVID Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CELU Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.2M market capitalization and -254.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OVID Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $424.6M market capitalization and -4693.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CELU vs OVID Key Questions & Quantitative Answers

As of Nov 20, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). CELU carries a Unified Composite Score of 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin), whereas OVID carries 52.3/100 (HOLD) at $2.20 (1.8x Forward P/E, -4693.7% operating margin). Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (52.3/100 HOLD vs. CELU 42.9/100 HOLD) and 1.04β · 97% Vol risk profile, whereas CELU leads top-line expansion (-5.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CELU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9); meanwhile OVID is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CELU leads the Growth & Scale pillar: CELU posts -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin), compared with OVID at -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), CELU cumulative revenue shifted +200.0% while OVID shifted +0.0%. In operating R&D and SG&A reinvestment, CELU deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OVID.

OVID screens cheaper on headline valuation multiples. CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin), whereas OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CELU (-6367.2% ROE) versus OVID (-35.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk). By comparison, OVID carries 11.7% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.04β · 97% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.